Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Phase 1 clinical data for IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 through June 4 in Chicago, Ill., and the 12th International Conference on Malignant Lymphoma (ICML), which is being held from June 19 through June 22 in Lugano, Switzerland. Key clinical results to be presented during both meetings include updated data from Infinity’s Phase 1 study evaluating the safety, clinical activity and pharmacokinetics of IPI-145 in people with advanced hematologic malignancies (blood cancers).
Help employers find you! Check out all the jobs and post your resume.
